@yorkie67 I’m so glad to hear Tagrisso is helping. When you say “working,” do you mean the spots are holding steady or even shrinking? Either way—that’s a win, and I’ll celebrate with you!

A few thoughts that might help: for many of us, Tagrisso is our medium-term hope. Cancer cells tend to grow quickly and dodge normal cell death (apoptosis). Tagrisso doesn’t “hunt down” every cancer cell; it blocks the signaling that turns healthy cells into cancer cells, slowing or stopping spread. That pause can give your body time to do what it’s designed to do—and that’s one reason people with EGFR exon 19 or 21 mutations can live well for many years on targeted therapy.

To your question about “what’s next”: we’re not wishing for “Tagrisso v2” so much as looking toward treatments that can directly eliminate remaining cancer. Sometimes tumors learn to bypass Tagrisso, and the path forward depends on what changes they develop. That’s why updated biomarker testing is so important—it tells your team what to target. Chemo and immunotherapy can help in certain scenarios, but it’s very individual. Amivantamab (sometimes paired with lazertinib) is one option in the toolkit because it targets EGFR and the MET pathway; whether it fits depends on your specific results. And just to avoid confusion—when you write “mets,” if you mean metastases, there may also be local options depending on where they are.

If you want to dig deeper, the International Association for the Study of Lung Cancer (iaslc.org) is a great home base. Their Lung Cancer 360 resources—webinars, posters, conference updates—are excellent, and the annual Targeted Therapies of Lung Cancer meeting shares the latest on drugs like Tagrisso. MD Anderson in Houston also has widely respected EGFR expertise if you ever want another set of eyes.

I know I can be wordy, but I hope this offers clarity and hope. You’re not alone in this. Keep the questions coming, and we're cheering for you every step!